Anti Covid pill, the European drug agency Ema starts the review of the data available on the antiviral pill molnupiravir to support possible national decisions on the early use of this drug against the coronavirus. The EU regulatory body and the heads of the national drug agencies of the member states (HMA) have agreed on the need for further guidance on Covid treatments in light of the increase in infection rates and deaths due to Sars-CoV-2 across the country. ‘European Union, reads an update on the molnupiravir issue released today.
To this end, the note reads, EMA “is reviewing the available data on the use of molnupiravir (also known as MK 4482 or Lagevrio *) to support national authorities who may decide on the use of this medicine for treatment. of Covid before its authorization “. While the more comprehensive ongoing review is underway in view of a possible application for a marketing authorization, EMA’s Committee for Medicinal Products for Human Use (CHMP) will therefore provide “EU-wide recommendations as soon as possible. , to help national authorities decide on the possible early use of the drug, for example in emergency settings “.
Molnupiravir is an oral antiviral developed by Merck Sharp & Dohme (MSD, known as Merck in the US and Canada), in collaboration with Ridgeback Biotherapeutics. Ema and the HMA network agencies “remain committed to accelerating the assessment of much-needed treatments and vaccines” for Covid, “while ensuring that they meet the EU’s high safety and efficacy standards. EMA will communicate the outcome of this review and that of the rolling review once completed “.